NCT00395434View on ClinicalTrials.gov

Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Tumors
Interventions
DRUG

Combretastatin A4 Phosphate (CA4P)

DRUG

Bevacizumab (Avastin)

Trial Locations (2)

HA6 2RN

Mount Vernon Hospital, Northwood

SM2 5PT

Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
lead

Mateon Therapeutics

INDUSTRY

NCT00395434 - Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter